Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: A randomised study

This trial tested the safety & consistency of the immune responses elicited by three consecutive lots of tetravalent dengue vaccine.

Research

Five-Year Antibody Persistence And Safety Following a Combined Haemophilus Influenzae Neisseria Meningitidis Tetanus Toxoid Vaccines

The purpose of this article is to investigate whether the number and timing of stressors experienced during pregnancy impacted longterm motor development at...

Research

Innate immunity in human newborn infants: prematurity means more than immaturity

Neonates, particularly those born prematurely, are exquisitely vulnerable to life-threatening infections. This increased susceptibility to infection...

Research

Nasopharyngeal carriage of Haemophilus haemolyticus in otitis-prone and healthy children

Haemophilus haemolyticus is often incorrectly categorized as nontypeable Haemophilus influenzae (NTHI) upon culture. PCR analyses of 266 NTHI-like nasopharyngea

Research

Complexity of Influenza Outbreaks during the World Youth Day 2008 Mass Gathering and its Impact on Community Seasonal Influenza Activity

How Influenza outbreaks during mass gatherings have been rarely described, and detailed virologic assessment is lacking.

Research

Skull base osteomyelitis: Fungal versus Bacterial Infection

An 18-year (1990-2007) retrospective review of patients with Skull-base osteomyelitis (SBO) presenting to Westmead Hospital was performed.

Research

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papilloma Virus

We conducted a noninferiority immunogenicity study to bridge the efficacy findings in young women to preadolescent and adolescent girls and boys...

Research

Predominance of nontypeable haemophilus influenzae in children with otitis media

In Australia the 7-valent pneumococcal conjugate vaccine (PCV7) is administered at 2, 4 and 6 months of age, with no booster dose.

Research

Pneumococcal conjugate vaccination at birth in a high-risk setting: No evidence for neonatal T-cell tolerance

Concerns about the risk of inducing immune deviation-associated "neonatal tolerance" as described in mice have restricted the widespread adoption...

Research

Slam and dc-sign measles receptor polymorphisms and their impact on antibody and cytokine responses to measles vaccine

Despite the use of measles vaccine, measles virus continues to circulate and cause severe disease